| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 12/18/2012 | US8333958 HSA-free formulations of interferon-Beta |
| 12/18/2012 | CA2754102C Monoclonal antibodies and compositions comprising such useful for inhibition of .alpha.v.beta.5 mediated angiogenesis |
| 12/18/2012 | CA2716966C Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
| 12/18/2012 | CA2671776C Gal3 receptor antagonists for the treatment of depression |
| 12/18/2012 | CA2569077C Combinations comprising antimuscarinic agents and corticosteroids |
| 12/18/2012 | CA2569074C Combinations comprising antimuscarinic agents and pde4 inhibitors |
| 12/18/2012 | CA2568571C Combinations comprising antimuscarinic agents and corticosteroids |
| 12/18/2012 | CA2568568C Combinations comprising antimuscarinic agents and beta-adrenergic agonists |
| 12/18/2012 | CA2568566C Combinations comprising antimuscarinic agents and pde4 inhibitors |
| 12/18/2012 | CA2563674C .alpha.-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
| 12/18/2012 | CA2472163C Psoriasin expression by breast epithelial cells |
| 12/18/2012 | CA2407895C Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis |
| 12/18/2012 | CA2363486C Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol |
| 12/13/2012 | WO2012168161A1 Combination comprising umeclidinium and a corticosteroid |
| 12/13/2012 | WO2012168160A1 Dry powder inhaler compositions comprising umeclidinium |
| 12/13/2012 | US20120316241 Remedy for cartilage-related diseases |
| 12/13/2012 | US20120316189 Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients diagnosed or undiagnosed respiratory illness |
| 12/13/2012 | US20120316133 Aqueous iron carbohydrate complexes, their production and medicaments containing them |
| 12/13/2012 | US20120315634 Distinguishing pca3 messenger rna species in benign and malignant prostate tissues |
| 12/13/2012 | US20120315286 Compositions and methods related to tim 3, a th1-specific cell surface molecule |
| 12/13/2012 | US20120315264 Zwitterionic immunomodulators for the teatment of asthma and allergy |
| 12/13/2012 | US20120315258 Bacillus strains and methods for reducing e. coli disease and enhancing performance |
| 12/13/2012 | US20120315257 Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders |
| 12/13/2012 | CA2838031A1 Dry powder inhaler compositions comprising umeclidinium |
| 12/13/2012 | CA2838030A1 Combination comprising umeclidinium and a corticosteroid |
| 12/12/2012 | EP2532353A1 Herbal therapy for the treatment of asthma |
| 12/12/2012 | EP2532350A1 Pharmaceutical combination of a glucocorticoid receptor antagonist and a cortisol synthesis inhibitor for treating cushing's syndrome |
| 12/12/2012 | EP2532235A1 Inhibitors of bruton's tyrosine kinase |
| 12/12/2012 | EP2532234A1 Inhibitors of bruton's tyrosine kinase |
| 12/12/2012 | EP2531211A1 Method for sensitizing cells to cancer therapy |
| 12/12/2012 | EP2531199A2 Complex formulation comprising aspirin coated with barrier containing hydrophobic additive, and hmg-coa reductase inhibitor |
| 12/12/2012 | EP2531187A1 sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS |
| 12/12/2012 | EP2531182A1 Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| 12/12/2012 | CN1678734B Differentiation modulating agents and uses thereof |
| 12/12/2012 | CN102822200A Combination of anti-CTLA4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| 12/12/2012 | CN102821790A Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same |
| 12/12/2012 | CN102821760A New pharmaceutical composition suitable for treating persons affected by neurodegenerative or neurovascular diseases |
| 12/12/2012 | CN102821759A PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling |
| 12/12/2012 | CN102821754A Multilayer melt-extruded film |
| 12/12/2012 | CN102816792A Method for regulating expression, quantity and activity of heat shock protein 70 and application thereof |
| 12/12/2012 | CN102813935A Application of non-woven fabric in preparing drug for treating oral diseases and preparation |
| 12/12/2012 | CN102813927A Application of bone morphogenetic protein-4 in screening drugs for resisting cardiac hypertrophy, heart failure or cardiac fibrosis |
| 12/12/2012 | CN102813926A Application of miR-7 expression inhibitor in preparing medicines used for treating systemic lupus erythematosus |
| 12/12/2012 | CN102813925A Application of carbon monoxide releasing molecules in preparing medicines for inhibiting blood coagulation activation diseases |
| 12/12/2012 | CN102813924A Drug combination product for analgesia based on sinomenine |
| 12/12/2012 | CN102813923A Combination Therapy for the Treatment of Ocular Neovascular Disorders |
| 12/12/2012 | CN102813840A Application of pharmaceutical composition in preparing medicines used for preventing and treating diabetic cardiomyopathy |
| 12/12/2012 | CN102813753A Composition containing Cistanche deserticola or Herba Cynomorii and combination of chrysanthemum, taurine, lycopene, xanthophyll and beta-carotene |
| 12/12/2012 | CN102813635A Pharmaceutical composition |
| 12/12/2012 | CN102099027B Fulvic acid and antibiotic combination |
| 12/12/2012 | CN101987083B Preparation method for controlled release preparation, especial for zero-order release controlled release preparation |
| 12/12/2012 | CN101837129B Medicament composition containing cMet inhibitor, HDAC (Histone Deacetylases) inhibitor and EGFR (Epidermal Growth Factor Receptor) tyrosine kinase inhibitor and application thereof |
| 12/12/2012 | CN101801351B Solid preparation comprising alogliptin and metformin hydrochloride |
| 12/12/2012 | CN101757626B Pharmaceutical composition containing insulin-like growth factor-I receptor inhibitor and histon deacetylase (HDAC) inhibitor and application thereof |
| 12/12/2012 | CN101588810B Composition comprising trachelospermi caulis and pyrola japonica extracts for the treatment and prevention of inflammatory diseases |
| 12/12/2012 | CN101312746B Preparation containing iron(iii)-complexes and redox substances |
| 12/11/2012 | US8330026 Derivatives of the NF-κB inducing enzyme, their preparation and use |
| 12/11/2012 | US8329928 Compounds, compositions and methods |
| 12/11/2012 | US8329924 Compounds and methods for the treatment or prevention of Flavivirus infections |
| 12/11/2012 | US8329919 Salt hydrates |
| 12/11/2012 | US8329749 Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperuricemia |
| 12/11/2012 | US8329656 Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders |
| 12/11/2012 | US8329463 RNA interference mediating small RNA molecules |
| 12/11/2012 | US8329227 Compositions for improving mental performance |
| 12/11/2012 | US8329197 Ex vivo uses of immunostimulatory combinations |
| 12/11/2012 | US8329190 Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria |
| 12/11/2012 | US8329180 Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 12/11/2012 | US8329171 Method for treating psoriatic arthritis by administering an anti-IL-12 antibody |
| 12/11/2012 | US8329144 Diagnostic and therapeutic epitope, and transgenic plant |
| 12/11/2012 | CA2661042C Agents for blood-brain barrier delivery |
| 12/11/2012 | CA2650202C Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds |
| 12/11/2012 | CA2549467C A preventive agent for vasculitis |
| 12/11/2012 | CA2484632C Processes for forming a drug delivery device |
| 12/11/2012 | CA2477516C Pharmaceutical formulation comprising melatonin |
| 12/06/2012 | WO2012167061A1 OPSONIZED β-GLUCAN PREPARATIONS AND METHODS |
| 12/06/2012 | WO2012166533A1 D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders |
| 12/06/2012 | WO2012166008A1 Combination for treatment of diabetes mellitus |
| 12/06/2012 | WO2012165985A1 An analgesic pharmaceutical composition for oral administration |
| 12/06/2012 | WO2012165406A1 Psychic energizer agent and psychic energizer composition |
| 12/06/2012 | WO2012164535A1 Antioxidant composition for the reduction of the causes of reduced male reproductive capacity |
| 12/06/2012 | WO2012164241A1 Pharmaceutical antiretroviral composition |
| 12/06/2012 | WO2012163590A1 Anti-inflammatory composition |
| 12/06/2012 | WO2012163589A1 Polyphenol composition for preventing or treating atherosclerosis |
| 12/06/2012 | WO2012163365A1 Combinations of serotonin receptor agonists for treatment of movement disorders |
| 12/06/2012 | WO2012162777A1 Oral pharmaceutical composition comprising a proton pump inhibitor and a prokinetic agent that can be used in excess stomach acid disorders |
| 12/06/2012 | WO2012106287A8 Methods of treating acute kidney injury with retinoic acid |
| 12/06/2012 | US20120310144 Vision through photodynamic therapy of the eye |
| 12/06/2012 | US20120309936 Reducing the immunogenicity of fusion proteins |
| 12/06/2012 | US20120309823 Percutaneous absorption preparations |
| 12/06/2012 | US20120309727 Combinations comprising antimuscarinic agents and pde4 inhibitors |
| 12/06/2012 | US20120309726 Combinations comprising antimuscarinic agents and pde4 inhibitors |
| 12/06/2012 | US20120308671 Nasal ointment based on white petroleum jelly |
| 12/06/2012 | US20120308534 Neural progenitor cell populations |
| 12/06/2012 | US20120308518 Methods of using regenerative cells in the treatment of stroke and related diseases and disorders |
| 12/06/2012 | CA2837381A1 D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders |
| 12/06/2012 | CA2835715A1 Anti-inflammatory composition |
| 12/06/2012 | CA2835272A1 Pharmaceutical antiretroviral composition |
| 12/05/2012 | EP2529734A1 Nitrate esters and their use for the treatment of muscle and muscle related diseases |
| 12/05/2012 | EP2528613A1 Method for treating liver disorders with receptor associated protein ( irp) peptide-fucosidase inhibitor conjugates |
| 12/05/2012 | EP2528607A2 Compositions and methods for reversing corticosteroid resistance or treating respiratory infections |